Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system (vol 151, pg 457, 2016)

被引：0

|

作者：

Ioannou, G. N.

Beste, L. A.

Chang, M. F.

机构：

来源：

GASTROENTEROLOGY | 2016年 / 151卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：1253 / 1253

页数：1

相关论文

共 35 条

[31] REAL-WORD EFFECTIVENESS OF 8, 12 AND 24 WEEKS LEDIPASVIR (LDV)/SOFOSBUVIR (SOF)-BASED THERAPY FOR HEPATITIS C VIRUS (HCV) GENOTYPE 1: ANALYSIS IN A LARGE INTEGRATED HEALTH CARE SYSTEM
Lai, J.
Witt, M.
Witt, D.
JOURNAL OF HEPATOLOGY, 2016, 64 : S778 - S778
[32] Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir plus /- ribavirin (3D±R) in patients with genotype (GT) 1 chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection compared with other standards of care in the US
Virabhak, Suchin
Johnson, Scott J.
Parise, Helene
Juday, Timothy R.
Wang, Alice
Sanchez, Yuri
Saab, Sammy
HEPATOLOGY, 2015, 62 : 773A - 774A
[33] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial (vol 16, pg 685, 2016)
Manns, M.
Samuel, D.
Gane, E. J.
LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 636 - 636
[34] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial (vol 1, pg 36, 2016)
Waked, I
Shiha, G.
Qaqish, R. B.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : E1 - E1
[35] Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial (vol 383, pg 515, 2014)
Lawitz, E.
Poordad, F. F.
Pang, P. S.
LANCET, 2014, 383 (9920): : 870 - 870

← 1 2 3 4 →